The clinical cohort project Clinical Surveillance of HIV Disease in Germany (ClinSurv HIV) was initiated in 1999 as a collaboration between major HIV treatment centres and the RKI. During the implementation period the project was supported by the BMG, and subsequently for a limited time by the German Ministry for Education and Research [Bundesministerium für Bildung und Forschung (BMBF)]. The study design allows us to assess the associations between demographic and clinical characteristics, different treatment regimens and trends

of disease progression over time under routine Selleck Navitoclax clinical care conditions. The cohort represents the clinical reality of HIV treatment AG-014699 manufacturer and care for a large proportion of HIV-infected patients in Germany. Comparable cohort studies currently under way in other European countries are the UK Collaborative HIV Cohort (CHIC) Study [7], the Italian Cohort of Patients Naïve to Antiretrovirals (ICONA) [8] and the Swiss Cohort Study (SHCS) [9]. Each of these cohorts includes a more or less representative sample of national treatment centres specializing in HIV care. They monitor changes over time in factors such as the frequency of AIDS-defining illnesses, survival and, more generally, the progression of HIV disease, and the uptake of and response to

ART; they also identify factors associated with virological and immunological response to ART, or the clinical outcome of ART in general. The aim of this paper is to Oxalosuccinic acid give an overview of 10 years of data collection and continuous publication of results from the German ClinSurv HIV project. The objective of this cohort study is to make a significant contribution to the literature addressing current and future epidemiological and clinical research questions in European countries such as Germany

with a concentrated HIV epidemic. The ClinSurv HIV project is a clinical epidemiological network and is designed as a multicentre open observational cohort study. The prospective enrolment of patients started on 1 January 1999. In all, 18 experienced HIV treatment centres have contributed data since the start of the cohort study. Currently, 11 centres continue to enrol patients actively and prospectively, fulfilling defined data quality control criteria. Data from two additional treatment centres are included; however, these centres do not enrol additional patients prospectively. The majority of the centres are out-patient departments (OPDs) at university hospitals with computer-based documentation systems. Some of the centres are OPDs directed by private practitioners. All centres are authorized to treat patients in the national public health assurance system.